Ovarian Cancer | Specialty

Promising PARP Inhibitor Strategies Emerging in Platinum-Sensitive Ovarian Cancer

July 24th 2019

Richard T. Penson, MD, MRCP, discusses novel strategies with PARP inhibitors and the use of biomarkers to create more personalized treatments for patients with platinum-sensitive ovarian cancer.

Evaluating Surgery and Angiogenesis Inhibition in Recurrent Ovarian Cancer

July 21st 2019

Angeles Alvarez Secord, MD, discusses the available treatment modalities for patients with platinum-sensitive and -resistant recurrent ovarian cancer.

Molecular Testing Continues to Evolve in Ovarian Cancer

July 19th 2019

Jubilee Brown, MD, discusses the importance of molecular testing immediately after an ovarian cancer diagnosis and how molecular testing will shape the field of ovarian cancer.

Quest Continues to Extend Reach of Immunotherapy, PARP Inhibitors in Ovarian Cancer

July 17th 2019

Matthew Powell, MD, discusses the trials that are generating excitement for combination immunotherapy as well as the impact of PARP inhibitors in the treatment of patients with ovarian cancer.

SOLO-1 Data Encourage Molecular Testing Immediately at Ovarian Cancer Diagnosis

July 17th 2019

Thomas Herzog, MD, discusses recent changes in the ovarian cancer landscape, specifically PARP inhibitors and the optimal use of bevacizumab.

Debate Continues Between Upfront Surgery and Neoadjuvant Chemo in Advanced Ovarian Cancer

July 16th 2019

R. Wendel Naumann, MD, discusses the criteria for primary debulking versus neoadjuvant chemotherapy in patients with advanced ovarian cancer.

Frontline Maintenance Niraparib Improves PFS in Ovarian Cancer

July 15th 2019

Niraparib as a maintenance treatment demonstrated a statistically significant improvement in progression-free survival compared with placebo in patients with ovarian cancer following first-line platinum-based chemotherapy, regardless of biomarker status, meeting the primary endpoint of the phase III PRIMA (ENGOT-OV26/GOG-3012) trial.

New Biomarkers for Responses Are Explored in Late-Stage Ovarian Cancer

July 4th 2019

The identification of appropriate biomarkers for evaluating responses to therapy would be beneficial across all stages of ovarian cancer, from early to advanced.

Dr. Cristea on Investigational Maintenance Strategies in Ovarian Cancer

July 2nd 2019

Mihaela C. Cristea, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, discusses investigational maintenance strategies in advanced ovarian cancer.

Leave No One Behind: Optimizing Targeted Therapies in Ovarian Cancer

July 1st 2019

The development of targeted therapies, including bevacizumab (Avastin) and 3 PARP inhibitors, is changing treatment paradigms for women with epithelial ovarian cancer.

Dr. Penson on Olaparib Monotherapy Vs Chemo in Ovarian Cancer

June 20th 2019

Richard T. Penson, MD, MRCP, associate professor, Harvard Medical School, and clinical director, Medical Gynecologic Oncology, Massachusetts General Hospital, compares olaparib (Lynparza) monotherapy with chemotherapy for patients with relapsed germline BRCA-mutated (gBRCAm) platinum-sensitive ovarian cancer.

Frontline Maintenance Olaparib Approved in Europe for Ovarian Cancer

June 18th 2019

The European Commission has approved olaparib as a single agent for the maintenance treatment of adult patients with advanced BRCA1/2-mutated germline and/or somatic high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response following first-line platinum-based chemotherapy.

Moving Molecular Testing to the Frontlines of Ovarian Cancer

June 10th 2019

Mihaela C. Cristea, MD, emphasizes the use of molecular testing over tumor testing in ovarian cancer.

Sorting Through Unanswered Questions in Ovarian Cancer

June 10th 2019

Thanh H. Dellinger, MD, provides insight on the treatment of patients with newly diagnosed advanced ovarian cancer.

SOLO-1 Olaparib Trial Fosters Novel Applications of Frontline Maintenance in Ovarian Cancer

June 7th 2019

Mihaela C. Cristea, MD, discusses the impact of the SOLO-1 trial on current approaches to frontline maintenance therapy as well as the trials that are underway with niraparib, rucaparib, and the investigational PARP inhibitor veliparib.

Olaparib Extends PFS, Hits High Response in Confirmatory BRCA+ Ovarian Cancer Trial

June 4th 2019

The PARP inhibitor olaparib reduced the risk of disease progression or death by 38% versus chemotherapy in patients with platinum-sensitive, relapsed, germline BRCA1/2-mutated ovarian cancer who received at least 2 prior lines of chemotherapy.

Niraparib/Bevacizumab Combo Active in Recurrent Ovarian Cancer

June 4th 2019

A chemotherapy-free doublet for platinum-sensitive recurrent ovarian cancer more than doubled progression-free survival as compared with single-agent PARP inhibitor.

ACA Improved Ovarian Cancer Diagnosis and Time to Treatment

June 2nd 2019

Pre-Medicare-aged women with ovarian cancer were more likely to be diagnosed at an early stage and receive treatment within 30 days of diagnosis after passage of the Affordable Care Act than before.

ASCO 2019: Dr. Plimack Highlights Practice-Changing Data for Genitourinary Cancers

June 2nd 2019

ASCO 2019: Dr. Ferris Discusses the Latest Data in Head and Neck Cancer

June 2nd 2019